In 2021, Blogs & News

What’s New at HP Ingredients?

As you wind up 2021 editorial and embark on 2022 calendar development, HP Ingredients can provide fresh, qualitative information for your planned features.

Our new tagline, “Where science never sleeps” represents our significant continual investment into scientific discovery of how our ingredients work in vivo and how they affect health parameters in human subjects.

In addition, as a corporate entity, we are also growing.

Here, we present you with our latest news and studies that are recently published within the past 2 years and what studies are currently ongoing.



HP Ingredients purchased a stake in H&AD S.r.l., manufacturer of Bergamonte®, a patented bergamot polyphenolic extract that is supported by evidence-based human clinicals. Annie Eng is now one of the four Directors of the Company. Annie Eng and Hame Persaud, Executive Vice President of HP Ingredients, will assume a key role to oversee all general marketing and sales of H&AD’s product offerings worldwide.

New Published Human Clinicals:
1. Atherogenic Index Reduction and Weight Loss in Metabolic Syndrome Patients Treated with A Novel Pectin-Enriched Formulation of Bergamot Polyphenols
Nutrients 2019, 11, 1271
Antonio Soccorso Capomolla, Elzbieta Janda, Sara Paone, Maddalena Parafati, Tomasz Sawicki, Rocco Mollace, Salvatore Ragusa and Vincenzo Mollace

2. Bergamot Polyphenolic Fraction Supplementation Improves Cognitive Functioning in Schizophrenia. Data From an 8-Week, Open-Label Pilot Study
Journal of Clinical Psychopharmacology: August 2017 – Volume 37 – Issue 4 – p 468-471
Antonio Bruno, MD, PhD, Gianluca Pandolfo, MD, PhD, Manuela Crucitti, MD, Clemente Cedro, MD, PhD, Rocco Antonio Zoccali, MD, and Maria Rosaria Anna Muscatello, MD, PhD

Pending Human Clinicals:
Efficacy of BPE Complex on Lipidemic Profile and PCSK9 Plasma Level in Atorvastatin-treated Hyper-cholesterolemic Patients
N.O. Max (Bergamonte + L Citruline) for sport nutrition

New In vivo In Vitro
1. Oxidative Imbalance and Kidney Damage in Cafeteria Diet-Induced Rat Model of Metabolic Syndrome: Effect of Bergamot Polyphenolic Fraction
Antioxidants (Basel). 2019 Mar; 8(3): 66. Daniele La Russa, Francesca Giordano, Alessandro Marrone, Maddalena Parafati, Elzbieta Janda and Daniela Pellegrino
2. The effect of bergamot polyphenolic fraction on lipid transfer protein system and vascular oxidative stress in a rat model of hyperlipemia
l. Lipids in Health and Disease (2019) 18:115 Vincenzo Musolino, Micaela Gliozzi, Saverio Nucera, Cristina Carresi, Jessica Maiuolo, Rocco Mollace, Sara Paone, Francesca Bosco, Federica Scarano, Miriam Scicchitano, Stefano Ruga, Maria Caterina Zito, Carmen Colica, Roberta Macrì, Ernesto Palma, Salvatore Ragusa, Carolina Muscoli and Vincenzo Mollace


New Published Human Clinicals:
1.A double‐blind, randomized, placebo‐controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis
Phytotherapy Research. Volume33, Issue5 May 2019 Pages 1469-1479.
Juan L. Hancke Shalini Srivastav Dante D. Cáceres Rafael A. Burgos

New In vivo In Vitro
1.Andrographolide As a Potential Inhibitor of SARS-CoV-2 Main Protease: An In Silico Approach
Journal of Biomolecular Structure and Dynamics, Apr 2020. Sukanth Kumar Enmozhi, Kavitha Raja, Irudhayasamy Sebastine, Tiruchirappalli, & Jerrine Joseph
2.Possible inhibitors of ACE2, the receptor of 2019-nCoV
Pharmacology & Toxicology February 2020. Qinghua Cui, Chuanbo Huang, Xiangwen Ji, Wanlu Zhang, Fenghong Zhang, Liang Wang

3.Computational Investigation on Andrographis paniculata Phytochemicals to Evaluate Their Potency Against SARS-CoV-2 in Comparison to Known Antiviral Compounds in Drug Trials.

Natarajan Arul Murugan, Chitra Jeyaraj Pandian and Jeyaraman Jeyakanthan

4.Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis
Cell Death & Disease volume 10, Article number: 957 (2019). Jian Gao, Shuang Peng, Xinni Shan, Guoliang Deng, Lihong Shen, Jian Sun, Chunhong Jiang, Xiaoling Yang, Zhigang Chang, Xinchen Sun, Fude Feng, Lingdong Kong, Yanhong Gu, Wenjie Guo, Qiang Xu & Yang Sun

5.Restoration of HDAC2 and Nrf2 by Andrographolide Overcomes Corticosteroid Resistance in Chronic Obstructive Pulmonary Disease.
British Journal of Pharmacology. Apr 2020
Wupeng Liao, Albert Y. H. Lim, W. S. Daniel Tan, John Abisheganaden, W. S. Fred Wong

Ongoing human clinical trials:
Open-label clinical trial conducted in Chile to define and evaluate the effects of consuming 150 mg of ParActin® per day for three months on >300 frontline healthcare workers. The study evaluate the efficacy of ParActin® on immune resistance in this population.
Double-blind, randomized, placebo-controlled seven-day study will be conducted on 357 adults who have upper respiratory tract challenges (Covid + and Covid -). The volunteers will be evaluated with the Wisconsin Upper Respiratory Symptom Survey-21 total severity scores or covid diary, as well as time taken to reach negative Covid RT-PCR swab test to determine efficacy. This study has four arms: 600 mg of ParActin®, 1,200 mg of MaquiCare® (also from HP Ingredients), combination of 600 mg of ParActin® with 1,200 mg of MaquiCare® maqui berry extract, and a placebo group.
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of 336 days Exposure of 300mg Paractin® on 111 patients Suffering from Osteoarthritis of Knee Joint.

Other news:
At the end of 2020, the government of Thailand approved a pilot study for the use of Andrographis paniculata as an herbal medicine to resolve early symptoms of COVID-19. Phase one of the Thai research initiative on Andrographis began in late June 2020 at two hospitals, where 12 subjects received either 60 mg or 100 mg capsules of the extract, three times per day. Phase two began in September 2020 with 60 subjects who were given either Andrographis or placebo.


New Published Human Clinicals:
1.Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study
BMC Neurology volume 16, Article number: 77 (2016). J. C. Bertoglio, M. Baumgartner, R. Palma, E. Ciampi, C. Carcamo, D. D. Cáceres, G. Acosta-Jamett, J. L. Hancke & R. A. Burgos

2. Efficacy of Andrographolide in Not Active Progressive Multiple Sclerosis: A Prospective Exploratory Double-Blind, Parallel-Group, Randomized, Placebo-Controlled Trial
BMC Neurology (2020) 20:173. Ethel Ciampi, Reinaldo Uribe-San-Martin, Claudia Cárcamo, Juan Pablo Cruz, , Ana Reyes, Diego Reyes, Carmen Pinto, Macarena Vásquez, Rafael A. Burgos and Juan Hancke

New Published Human Clinicals:
1. Effects of Eurycoma Longifolia Jack Supplementation Combined with Resistance Training on Isokinetic Muscular Strength and Power, Anaerobic Power, and Urinary Testosterone: Epitestosterone Ratio in Young Males
International Journal of Preventive Medicine. 2019; 10: 118. Chee Keong Chen, Foong Kiew Ooi, Nurul Ain Abu Kasim, and Mohd Asnizam Asari
2. The effect of Eurycoma Longifolia on the regulation of reproductive hormones in young males
Andrologia. 2021;00:e14001. Kai Quin Chan, Claire Stewart, Neil Chester, Sareena H. Hamzah, Ashril Yusof

3. Efficacy of Labisia pumila and Eurycoma longifolia standardized extracts on hot flushes, quality of life, hormone and lipid profile of peri-menopausal and menopausal women: a randomised, placebo-controlled study
Food & Nutrition Research 2020. Sasikala M. Chinnappan, Annie George, Malkanthi Evans, and Joseph Anthony.
4. Effect of Eurycoma longifolia Standardised Aqueous Root Extract–LJ100® on Testosterone Levels and Quality of Life in Ageing Male Subjects: A Randomised, Double-blind, Placebo-Controlled Multicentre Study (Pending Publication)
Randomised, double-blind, placebo-controlled study of 105 male subjects aged 50–70 years with a testosterone level <300 ng/dl, BMI ≥18 and ≤30.0 kg/m2. The subjects were given either LJ100® 100 mg, 200 mg or placebo daily for 12 weeks. The primary outcomes were changes in serum total and free testosterone levels. The secondary outcomes included changes in sex hormone binding globulin (SHBG), dihydroepiandrosterone (DHEA), ageing male symptoms (AMS) score, fatigue severity scale (FSS), BMI, HbA1c, insulin like growth factor-1 (IGF-1), thyroid function tests (T3, T4, TSH, Free T3), cortisol and muscle strength. Complete blood count, liver and renal function tests, lipid profile were measured as safety endpoints.

New In vivo In Vitro
1. Brain Cortical and Hippocampal Dopamine: A New Mechanistic Approach for Eurycoma longifolia Well-Known Aphrodisiac Activity and Its Chemical Characterization
Evidence-Based Complementary and Alternative Medicine Volume 2019, Article ID 7543460.
Shahira M. Ezzat, Marwa I. Ezzat, Mona M. Okba, Salah M. Hassan, Amgad I. Alkorashy, Mennatallah M. Karar, Sherif H. Ahmed, and Shanaz O. Mohamed

2. Rho-Kinase II Inhibitory Potential of Eurycoma longifolia New Isolate for the Management of Erectile Dysfunction
Evid Based Complement Alternat Med. 2019: 4341592. Shahira M. Ezzat, Mona M. Okba, Marwa I. Ezzat, Nora M. Aborehab, and Shanaz O. Mohamed

3. Eurycoma longifolia, a promising suppressor of RANKL-induced differentiation and activation of osteoclasts: An in vitro mechanistic evaluation
Journal of Ayurveda and Integrative Medicine 10 (2019) 102e110. Hnin Ei Thu, Zahid Hussain, Isa Naina Mohamed, Ahmad Nazrun Shuid

4. Effect of herbal extract Eurycoma longifolia (Physta®) on female reproductive hormones and bone biochemical markers: an ovariectomised rat model study
BMC Complementary Medicine and Therapies (2020) 20:31.
Sasikala M. Chinnappan, Annie George, Godavarthi Ashok and Yogendra Kumar


New Published Human Clinicals:
1. Efficacy and safety of Eurycoma longifolia (Adapticort®) water extract plus multivitamins on quality of life, mood and stress: a randomized placebo-controlled and parallel study
Food Nutr Res. 2018; 62: 10.29219/fnr.v62.1374. Annie George, Jay Udani, Nurhayati Zainal Abidin, and Ashril Yusof


New Pending Human Clinicals:
A randomised, double-blind, placebo-controlled clinical study was designed to evaluate the efficacy and tolerability of CitruSlim® in body weight management in obese individuals, and the results were compared with that of placebo. A total of 97 participants were allocated, randomised, and treated with CitruSlim® high-dose (HD, 400 mg), CitruSlim® low-dose (LD, 200 mg) and placebo for 112 days. At the end of the study, CitruSlim® HD and CitruSlim® LD significantly reduced BMI compared to the placebo group and were well tolerated; however, it did not improve parameters associated with dyslipidaemia and metabolic disturbances. The study findings suggested that CitruSlim® was effective in reducing body weight in obese patients.

Recent Posts